3,4-Dimethoxyphenylboronic Acid

We are 3,4-Dimethoxyphenylboronic Acid CAS:122775-35-3 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Product Name: 3,4-Dimethoxyphenylboronic Acid
Other Name:
3,4-Dimethoxyphenylboronic Acid
3,4-Dimethoxybenzeneboronic Acid
CAS No: 122775-35-3
MF: C8H11BO4
MW: 181.98200
Density: 1.19g/cm3
Boiling point: 336.7ºC at 760 mmHg
Melting point: 245-250 °C(lit.)
Flash point: 157.4ºC
Refractive index: 1.517
UN Number: Not dangerous goods.
UN Proper Shipping Name: Not dangerous goods.
Transport hazard class: Not dangerous goods.
Packing group: Not dangerous goods.
 
Specification
Appearance: White powder
Assay: ≥98.0%
Water: ≤0.50%
 
Application
Be used as pharmaceutical intermediate.
 
Package: 25kg/drum, can also be designed according to customer requirements.
Storage: Store in cool place. Keep container tightly closed in a dry and well-ventilated place.

3,4-Dimethoxyphenylboronic Acid


Related News: The clinical trial International Study of Phase 3 IV RigosErtib, or INSPIRE, was finalized following guidance received from the U.S. Food and Drug Administration and European Medicines Agency.52602-39-8 The clinical trial International Study of Phase 3 IV RigosErtib, or INSPIRE, was finalized following guidance received from the U.S. Food and Drug Administration and European Medicines Agency.5-Bromo-2-chloro-3-fluoropyridine The clinical trial International Study of Phase 3 IV RigosErtib, or INSPIRE, was finalized following guidance received from the U.S. Food and Drug Administration and European Medicines Agency.2-Bromoanisole CAS:578-57-4 DMF is the main management method for APIs in developed countries in Europe and the United States. Under the DMF system, API companies can submit DMF filing documents to the regulatory authority at any time, but the regulatory authority will not conduct technical reviews on them. When the drug is administered, the regulatory authority will associate and review the drug substance and the preparation.DMF is the main management method for APIs in developed countries in Europe and the United States. Under the DMF system, API companies can submit DMF filing documents to the regulatory authority at any time, but the regulatory authority will not conduct technical reviews on them. When the drug is administered, the regulatory authority will associate and review the drug substance and the preparation.

Related Products
Product Name
2,4-Difluorobenzoic acid View Details
Benzyl (S)-(-)-1,2,3,4-tetrahydro-3-isoquinolinecarboxylate p-toluenesulfonic acid salt View Details
Acetyl bromide View Details
Methyl 3-formyl-2-nitrobenzoate manufacturer chenodeoxycholic acid manufacturer Estratetraenol manufacturer (S)-1,2,3,4-Tetrahydro-1-Naphthoic Acid manufacturer 3-Bromo-5-cyanobenzotrifluoride manufacturer